Atai Beckley Inc.(ATAI)

$7.26—

Chart

Atai Beckley Inc.(ATAI)

NASDAQ

$7.26—

Chart Studio

ATAI(ATAI)

ATAI

Overview Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-0.11

Nov 11, 2026 · Reports before open

Revenue Estimate

$266,667

Analyst Sentiment

Wall St. Consensus

Hold

8 analysts·Limited coverage

Score

0 Buy (0%)8 Hold (100%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

00%

Hold

8100%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$7.45

+2.6%

Consensus

$7.50

+3.3%

Bull

$8.00

+10.2%

12-Month Target Range8 analysts

$7.45$7.50$8.00

Current $7.26Consensus

Current Price

$7.26

Upside to Consensus

$0.24

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev-52.01%

EPS—

FY2028

Rev+25.00%

EPS—

FY2029

Rev+9662.46%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$1M	$650,000	$812,500	$79M	$215M
Low	$1M	$643,048	$803,810	$78M	$213M
High	$1M	$660,427	$825,534	$81M	$218M
EBITDA Avg	$-1M	$-650,000	$-812,500	$-79M	$-215M
Low	$-1M	$-660,427	$-825,534	$-81M	$-218M
High	$-1M	$-643,048	$-803,810	$-78M	$-213M
EBIT Avg	$-1M	$-650,000	$-812,500	$-79M	$-215M
Low	$-1M	$-660,427	$-825,534	$-81M	$-218M
High	$-1M	$-643,048	$-803,810	$-78M	$-213M
Net Income Avg	$-154M	$-89M	$-91M	$-77M	$-43M
Low	$-158M	$-125M	$-143M	$-79M	$-44M
High	$-68M	$-53M	$-40M	$-76M	$-43M
EPS Avg	$-0.42	$-0.43	$-0.43	$-0.34	$-0.19
Low	$-0.70	$-0.55	$-0.63	$-0.35	$-0.20
High	$-0.30	$-0.24	$-0.18	$-0.34	$-0.19
Analysts (Rev / EPS)	9 / 7	7 / 8	11 / 12	5 / 9	5 / 5

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$111,111	$133,333	$2M	$2M	$2M	$225,000
Low	$111,111	$133,333	$2M	$2M	$2M	$225,000
High	$111,111	$133,333	$2M	$2M	$2M	$225,000
EBITDA Avg	$-111,111	$-133,333	$-2M	$-2M	$-2M	$-225,000
Low	$-111,111	$-133,333	$-2M	$-2M	$-2M	$-225,000
High	$-111,111	$-133,333	$-2M	$-2M	$-2M	$-225,000
EBIT Avg	$-111,111	$-133,333	$-2M	$-2M	$-2M	$-225,000
Low	$-111,111	$-133,333	$-2M	$-2M	$-2M	$-225,000
High	$-111,111	$-133,333	$-2M	$-2M	$-2M	$-225,000
Net Income Avg	$-42M	$-44M	$-35M	$-35M	$-37M	$-38M
Low	$-53M	$-48M	$-35M	$-35M	$-37M	$-38M
High	$-34M	$-40M	$-35M	$-35M	$-37M	$-38M
EPS Avg	$-0.12	$-0.12	$-0.10	$-0.10	$-0.10	$-0.10
Low	$-0.15	$-0.13	$-0.10	$-0.10	$-0.10	$-0.10
High	$-0.09	$-0.11	$-0.10	$-0.10	$-0.10	$-0.10
Analysts (Rev / EPS)	12 / 6	10 / 4	9 / 1	9 / 1	9 / 1	9 / 1

Earnings Surprises

Recent Analyst Actions

Aug 12, 2026Deutsche Bank

Deutsche Bank Downgrades AtaiBeckley Inc (ATAI) to Hold

Target:$8.00

+11.0%from $7.21

Jul 20, 2026H.C. Wainwright

AtaiBeckley downgraded to Neutral from Buy at H.C. Wainwright

Target:$7.50

+3.9%from $7.22

Jul 20, 2026Berenberg Bank

AtaiBeckley downgraded to Hold from Buy at Berenberg

Target:$7.45

+3.2%from $7.22

Jul 16, 2026Jefferies

AtaiBeckley downgraded to Hold from Buy at Jefferies

Target:$7.50

+4.9%from $7.15

Jul 16, 2026Canaccord Genuity

AtaiBeckley downgraded to Hold from Buy at Canaccord

Target:$8.00

+11.9%from $7.15

Jul 7, 2026Canaccord Genuity

AtaiBeckley price target raised to $17 from $15 at Canaccord

Target:$17.00

+242.7%from $4.96

Apr 20, 2026Canaccord Genuity

AtaiBeckley price target raised to $15 from $14 at Canaccord

Target:$15.00

+188.5%from $5.20

Mar 27, 2026Deutsche Bank

AtaiBeckley initiated with a Buy at Deutsche Bank

Target:$12.00

+258.2%from $3.35

Mar 6, 2026Jefferies

Jefferies Reiterates Buy Rating on atai Life Sciences N.V (ATAI): "keen on ATAI's robust BPL-003 Phase IIb TRD results"

Target:$10.00

+195.0%from $3.39

Jan 20, 2026Guggenheim

Atai Beckley initiated with a Buy at Guggenheim

Target:$11.00

+202.2%from $3.64

Oct 22, 2025Canaccord Genuity

Atai Life Sciences price target raised to $14 from $11 at Canaccord

Target:$14.00

+138.5%from $5.87

Oct 13, 2025Needham

Atai Life Sciences initiated with a Buy at Needham

Target:$12.00

+135.3%from $5.10

May 20, 2025Jefferies

Phase 2a data for BPL-003 'encouraging' for Atai Life Sciences, says Jefferies

Target:$5.00

+143.9%from $2.05

Apr 3, 2024Maxim Group

Maxim Group Upgrades atai Life Sciences N.V (ATAI) to Buy

Target:$6.00

+220.9%from $1.87

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance